News

UC Davis team isolates fungus enzyme to cross blood-brain barrier

At the American Society for Microbiology's annual meeting this week, a team of researchers from the University of California, Davis, demonstrated a study showing that silicon nanoparticles they designed could penetrate the blood-brain barrier.

UPDATED: Alnylam's hepatitis B therapy shows promise in animal studies

RNAi specialist Alnylam is adding a hepatitis B virus therapy to its pipeline of candidates that employ its Enhanced Stabilization Chemistry-GalNAc-conjugate technology enabling subcutaneous dosing and plans to file an IND by the end of 2015.

Nanoparticles weaken and then kill cancer cells with two-drug timed release

Scientists at MIT have engineered a one-two punch for cancer that carries two drugs at a time and has been shown to shrink lung and breast tumors in mice. While other nanoparticles have carried multiple drugs, this one makes use of a specific timing mechanism to get the most out of each treatment.

North Carolina State researchers 'smuggle' drugs into cancer cells with ATP

North Carolina State researchers have developed a method to "smuggle" cancer drugs into cancer cells, enabling delivery of the treatment within the cell itself.

Boston College team makes zinc nano-cages for 'smart' cancer drug delivery

Researchers at Boston College have created a small cage out of metals and organic materials that can act as a "smart" delivery vehicle to carry cancer drugs.

MIT researchers deliver low doses of siRNA to lung endothelial cells

One of the chief drawbacks of RNA interference therapies so far has been the difficulty of delivering small interfering RNA to cells outside the liver. That's why a newly reported breakthrough in delivering siRNA to endothelial cells in the lung and other organs is a big deal.

Tonix's sublingual formulation for fibromyalgia reaches pivotal trial stage

Tonix Pharmaceuticals has completed enrollment in the 200-patient, placebo-controlled BESTFIT trial of sublingually delivered cyclobenzaprine for the treatment of fibromyalgia. 

Boston Scientific launches Promus Premier drug-eluting stent in Japan

Boston Scientific rolled out its Promus Premier next-generation drug-eluting coronary stent system in Japan, part of the company's sales and marketing strategy as it looks for a blockbuster product to kick-start its revenue growth.

Icon begins pivotal late-stage trial of sustained-release postsurgery cataract treatment

Icon Biosciences has advanced its sustained-release therapy for inflammation after cataract surgery to a pivotal late-stage study. With one injection postsurgery, Icon's platform releases anti-inflammatory drugs that currently require multiple topical applications daily.

Direct injection of drugs to back of eye shows potential

Clearside Biomedical presented human and animal study data showing the benefits of directly injecting medication into the eye's posterior suprachoroidal space at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL.

Double-locked virus needs two enzyme 'keys' to release drugs

Researchers at Rice University in Texas have developed a new kind of drug delivery particle: a "tunable" virus that releases a treatment only in the presence of not one but two different enzymes that show elevated levels at the site of a tumor.

Braeburn Pharmaceuticals to clinically test subdermal implant for treatment of opioid dependence

Braeburn Pharmaceuticals received the go-ahead from the FDA to initiate a new clinical trial of implants for the continuous subdermal delivery of buprenorphine to combat opioid dependence.

Novel glaucoma drug delivery platform described at ARVO conference

Startup Envisia Therapeutics is presenting the results of its ophthalmology research and technology allowing intracameral drug delivery at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL. 

Civitas announces positive results from Phase II inhaled levodopa trial

Civitas Therapeutics announced that its inhaled formulation of levodopa for the treatment of "off episodes" associated with Parkinson's disease met its primary clinical endpoint in a Phase II trial.

Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall

Some analysts raised their eyebrows at Oramed's preliminary midstage oral insulin data in late January. Now the Jerusalem company has announced further details of the trial that bring to light a dosing issue, and shares have continued their downward spiral ever since.

Zogenix retaining rights to DosePro delivery technology in transaction with Endo

Zogenix is selling its Sumavel DosePro Needle-free Delivery System for migraines to Endo International, but don't be fooled--it is maintaining ownership of the delivery technology upon which the product is based.

Johns Hopkins team delivers cancer-killing DNA to mouse brains with nanovehicles

Johns Hopkins researchers published a study showing they can use biodegradable nanoparticles to carry DNA to brain cancer cells. The animal study suggests that these vehicles could deliver what they call "death genes" to the cells, treating the cancer while preserving healthy brain cells in the process.

Cynapsus makes progress on sublingually delivered Parkinson's therapy

Cynapsus Therapeutics' sublingually delivered reformulation of the drug used to treat advanced Parkinson's disease cleared an initial clinical hurdle, the company said April 24.

Imaging technique maps transdermal drug migration

A team of chemistry professors has developed a method to monitor chemicals as they enter the skin, giving them a better idea of how fast and by which pathways the small molecules permeate the surface.

Hydrocarbon double-stapling of peptides a new trick in fight against viruses

Researchers have developed a unique delivery mechanism that inhibits the respiratory syncytial virus using double-stapled peptides and nanoparticles. They believe their research has implications for the treatment of other viruses as well.